Superworth

Heron Therapeutics price to book ratio HRTX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
8.3×
10-year median
7.7×
Against its 10-year history
55th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.5× to 41.6×
Peer median
1.5×

Heron Therapeutics' price to book ratio is 8.3× as of Oct 23, 2026.

That is above its ten-year median of 7.7×, close to the middle of its last ten years.

Over that time it ranged from 2.5× in Mar 2020 to 41.6× in Nov 2016.

The median for 7 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.3×8.1×18.4×
202515.8×13.1×16.9×
2024n/m a value too high to mean anything
202321.7×10.1×24.3×
202213.2×5.4×18.2×
20217.8×5.7×10.8×
20206.9×2.5×7.2×
20197.6×3.6×8.1×
20184.6×4.3×33.1×
201724.6×6.8×31.3×
201628.7×4.6×41.6×
20156.8×2.8×22.2×
20143.5×2.1×10.5×
20136.9×1.9×7.5×
20122.7×2.6×13.3×
20112.4×2.1×3.2×

Against its peers

Companies in Drug Manufacturers - General nearest Heron Therapeutics' size, closest first, today.

CompanyPrice to book ratio
HRTXHeron Therapeutics8.3×
SPROSpero Therapeutics1.5×
ATNMActinium Pharmaceuticals1.6×
LFVNLifevantage2.2×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Heron Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.